On September 17, British American Tobacco (BAT) launched a report resource called "Omni™" on its official website.
According to BAT, The Omni™ is mainly aimed at scientists, public health organizations, regulators, policymakers, and investors. It gathers the latest progress made by BAT in Tobacco Harm Reduction, with the goal of helping adult smokers transition to smoke-free alternatives by providing products with lower risks compared to traditional cigarettes.
The "Omni™" report consists of nine chapters, discussing key issues related to tobacco harm reduction and providing evidence from the past decade of global efforts to reduce tobacco-related harm.
BAT has stated that its goal is to have 50 million new tobacco product users by 2030, with the revenue from these products accounting for 50% by 2035.
At the same time, BAT also acknowledges that in the process of promoting a smoke-free world, they face many challenges, including opposition from regulatory agencies and non-governmental organizations, market sales restrictions, heavy regulatory frameworks, industry research being questioned, and public misunderstandings about the risks of nicotine and smoke-free products. The company emphasizes that it will continue to reduce the health risks of traditional tobacco products through science and innovation.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
